North America RNAi Therapeutics Market is expected to reach US$ 598.60 Mn in 2027
Published Date : 12/10/2020

Report : North America RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)); Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Other); Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others); and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals)

Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeuticsin 2019

According to our new market research study on “North AmericaRNAi Therapeutics Marketto 2027 – Regional Analysis and Forecast – by Molecule Type,Route of Administration, Application, and End User”the North America RNAi therapeutics market is expected to reach US$ 598.60 million in 2027 from US$ 302.77 million in 2019, it is estimated to grow with a CAGR of 9.0% from 2020-2027. The report provides trends prevailing in the North AmericaRNAi therapeutics market and the factors driving the market growth along with those hindering it.

In 2019, the small interfering RNAs (siRNA) accounted for the highest share of the market. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Furthermore, MicroRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.

The growth of the North AmericaRNAi therapeuticsmarketis mainly attributed togrowing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and its benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region will eventually drive the market growth.However,the high cost of RNAi therapy development is the major factor hindering the market growth in North America.

Alnylam Pharmaceuticals, Inc;Arrowhead Pharmaceuticals, Inc;Quark;Rexahn Pharmaceuticals, Inc; and Arbutus Biopharma are among the leading companies operating in the North AmericaRNAi therapeuticsmarket.

The Report Segments North AmericaRNAi TherapeuticsMarketas Follows:

North AmericaRNAi TherapeuticsMarket– By MoleculeType

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)

North America RNAi TherapeuticsMarket – ByRoute of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others

North America RNAi TherapeuticsMarket – By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others

North America RNAi Therapeutics Market – By End User

  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories

North AmericaRNAi TherapeuticsMarket– By Country

  • US
  • Canada
  • Mexico

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
DOWNLOAD PDF BROCHURE